Thiazolidinediones in the treatment of insulin resistance and type II diabetes

Diabetes

Volumn 45, Issue 12, 1996, Pages 1661-1669

  Saltiel, Alan R ^a   Olefsky, Jerrold M ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; CELL NUCLEUS RECEPTOR; CIGLITAZONE; ENGLITAZONE; FATTY ACID; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR; PIOGLITAZONE; PLACEBO; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; GENE EXPRESSION REGULATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

EID: 0029995670     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.12.1661     Document Type: Review

References (51)

1. Fujita T, Sugiyama Y, Taketomi S, Shoda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z: Reduction of insulin resistance in obese and/or diabetic animals by 3[-4-(1 methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4 dione (ADD-3870, U-63287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810, 1983
2. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of a new and antidiabetic agent, CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1849-1888, 1988
3. Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hell XL, Danbury BH: Actions of a novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 39:1218-1227, 1990
4. Lee MK, Miles PDG, Khoursheed M, Gao KM, Mossa AR, Olefsky JM: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439, 1994
5. Khoursheed M, Miles PDG, Gao KM, Lee MK, Mossa AR, Olefsky JM: Metabolic effects of troglitazone on fat induced insulin resistance in the rat. Metabolism 44:1489-1494, 1995
6. Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A, Yamatomi K, Sasaki H: Thiazolidinidiones (AD-4533 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocrine J 40:343-349, 1993
7. Stevenson RW, McPherson RK, Genereux BE, Danbury BH, Kreutter DK: Antidiabetic agent Englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 40:1268-1274, 1991
8. Bowen L, Steven PP, Stevenson R, Shulman CI: The effect of CP-68772, a thiazolidine derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40:1025-1030, 1991
9. Oakes ND, Kennedy CJ, Jenkins AB, Laybulf DR, Chisholm DJ, Kraegen EW: A new antidiabetic agent, BHL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210, 1994
10. Hofmann C, Lorenz K, Colca JR: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129:1915-1925, 1991
11. Sugiyama Y, Shimura Y, Ikeda H: Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim Forschung 40:436-440, 1990
12. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H: Suppression of hepatic gluconeogenesis in chronic troglitazone (CS-045)-treated diabetic KK and C57BL/KSJ-db/db mice. Metabolism 44:486-490, 1995
13. Fujiwara T, Wade M, Fukuda K, Fukami M, Yoshioko S, Yokiosho T, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KSJ-db/db mice. Metabolism 40:1213-1218, 1991
14. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KJ: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with Metformin and troglitazone. Am J Physiol In press
15. Kraegen E, James D, Jenkins AB, Chishold OJ, Starlin LH: A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 38:1089-1093, 1989
16. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Itabashi A, Ishii J: Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and β-oxidation in fructose-fed rats. Metabolism 44:1626-1630, 1995
17. Castle CK, Colca JR, Melchior GW: Lipoprotein profile characterization of the KKA mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb 13:307-309, 1992
18. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
19. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
20. Valiquett T, Balagtas C, Whitcomb R: Troglitazone dose-response study in patients with NIDDM (Abstract). Diabetes 44 (Suppl. 1):109A, 1996
21. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
22. Tafuri SR: Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology. In press
23. Harris MI: Impaired glucose tolerance in the US population. Diabetes Care 12:464-474, 1989
24. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
25. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
26. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R: The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306, 1996
27. Saltiel AR: Diverse signaling pathways in the cellular actions of insulin. Am J Physiol 270:E375-E385, 1996
28. Kreutter DK, Andrews KM, Gibbs EM, Hutson NJ, Stevenson RW: Insulin-like activity of new antidiabetic agent CP68722 in 3T3-L1 adipocytes. Diabetes 39:1414-1419, 1990
29. Sandouk T, Reda D, Hofmann C: The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 133:352-359, 1993
30. El-Kebbi IM, Roser S, Pollet RJ: Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43:953-958, 1994
31. Kletzien RF, Clark SD, Ulrich RG: Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393-398, 1992
32. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioko S, Fujiwara T, Horikoshi H, Serizawa N: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 135:2279-2282, 1994
33. Sandouk T, Reda D, Hofmann C: Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol 264:C1600-C1608, 1993
34. Issemar I, Green S: Activation of a member of the hormone receptor superfamily by peroxisome proliferators. Nature 347:645-680, 1990
35. Claula A, Schwarz EJ, Dimaculangan DD, Lazar MA: Peroxisome proliferator-activated receptor (PPAR)γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135:798-800, 1994
36. Tontonoz P, Hu E, Graves DA, Budauon AL, Speigelman BM: mPPAR γ2: tissue specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234, 1994
37. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ). J Biol Chem 270:12953-12956, 1995
38. Wilson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor γ ago-nism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
39. Amri E-Z, Bonino F, Ailhaud G, Abumarad NA, Grimaldi PA: Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J Biol Chem 270:2367-2371, 1995
40. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404, 1995
41. Palmer CNA, Hsu MH, Grifin KJ, Johnson EF: Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 270:16114-16121, 1995
42. Braissant O, Foufelle F, Scott C, Dauce M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, βand γ in the adult rat. Endocrinology 137:354-366, 1996
43. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Speigelman B, Flier JS, Moller DE: Regulation of PPAR γ gene expression by nutrition and obesity in rodents. J Clin Invest 97:2553-2561, 1996
44. Jones PJ, Savory R, Borra HP, Bell AR, Gray TJB, Jenkins NA, Gilbert DJ, Copeland NC, Bell DR: Chromosomal localization, inducibility, tissue-specific expression and strain differences in three murine peroxisome proliferator activated receptor genes. Eur J Biochem 233:219-226, 1995
45. Yu K, Beyona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA: Differential activation of peroxisome proliferator activated receptors by eicosanoids. J Biol Chem 270:23975-2383, 1995
46. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812, 1995
47. Ciraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
48. Caro JF, Sinha MK, Raju JM, Itoop O, Paries WJ, Flickinger EL, Meelheim D, Pohm GL: Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest 79:1330-1337, 1987
49. Muller HK, Kellerer M, Ermel B, Muhlhofer A, Obermaier-Kusser B, Vogt B, Haring HU: Prevention by protein kinase C inhibitors of glucose-induced insulin receptor tyrosine kinase resistance in rat fat cells. Diabetes 40:1440-1448, 1991
50. Baler S, Kiehn R, Haring HU: Effect of CS-045 on the activity of insulin receptor kinase in the skeletal muscle of insulin resistant Zucker rats. Diabetes Stoffweschel 2:56-61, 1993
51. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, Haring HU: Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat 1 fibroblasts. Diabetes 43:447-453, 1994